BGT226 (NVP-BGT226) - CAS 1245537-68-1
Catalog number: 1245537-68-1
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C28H25F3N6O2.C4H4O4
Molecular Weight:
650.6
COA:
Inquire
Targets:
PI3K
Description:
BGT226 (NVP-BGT226) is a novel class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
N/A
MSDS:
Inquire
1.The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.
Simioni C1,2, Cani A1,2, Martelli AM3, Zauli G4, Alameen AA1,5, Ultimo S1, Tabellini G6, McCubrey JA7, Capitani S1,2, Neri LM1. Oncotarget. 2015 Jul 10;6(19):17147-60.
Hepatocellular carcinoma (HCC) is one of the most common lethal human malignancies worldwide and its advanced status is frequently resistant to conventional chemotherapeutic agents and radiation. We evaluated the cytotoxic effect of the orally bioavailable dual PI3K/mTOR inhibitor, NVP-BGT226, on a panel of HCC cell lines, since hyperactivated PI3K/Akt/mTOR signaling pathway could represent a biomolecular target for Small Inhibitor Molecules in this neoplasia. We analyzed the drug activity in both normoxia and hypoxia conditions, the latter playing often a relevant role in the induction of chemoresistance and angiogenesis.In normoxia NVP-BGT226 caused cell cycle arrest in the G0/G1 phase of the cell cycle, induced apoptosis and autophagy at low concentrations. Interestingly the drug inactivated p-Akt and p-S6 at < 10 nM concentration.In hypoxia NVP-BGT226 maintained its cytotoxic efficacy at the same concentration as documented by MTT assays and Western blot analysis.
2.Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines.
Katanasaka Y1, Kodera Y2, Yunokawa M2, Kitamura Y2, Tamura T3, Koizumi F4. Cancer Lett. 2014 Jun 1;347(2):196-203. doi: 10.1016/j.canlet.2014.02.025. Epub 2014 Mar 7.
Epidermal growth factor receptor (EGFR) and PI3K/mTOR pathway are drug targets for non-small cell lung cancer (NSCLC). Herein, we investigated anti-tumor effects of the combination of BGT226, a novel PI3K/mTOR dual inhibitor, and gefitinib on NSCLC cell lines which are high sensitive to gefitinib. The combination of BGT226 and gefitinib exhibited supra-additive growth inhibitory effects in PC-9 and HCC827 cells. Apoptotic induction and the inhibition of PI3K/mTOR signaling were enhanced by the combination. Significant tumor growth suppression was observed in xenograft model by the combination. These results suggest that the combination is effective in EGFR inhibitor-sensitive NSCLC therapy.
3.Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Kampa-Schittenhelm KM1, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM. Mol Cancer. 2013 May 24;12:46. doi: 10.1186/1476-4598-12-46.
BACKGROUND: Dysregulation of the PI3Kinase/AKT pathway is involved in the pathogenesis of many human malignancies. In acute leukemia, the AKT pathway is frequently activated, however mutations in the PI3K/AKT pathway are uncommon. In some cases, constitutive AKT activation can be linked to gain-of-function tyrosine kinase (TK) mutations upstream of the PI3K/AKT pathway. Inhibitors of the PI3K/AKT pathway are attractive candidates for cancer drug development, but so far clinical efficacy of PI3K inhibitors against various neoplasms has been moderate. Furthermore, specific MTORC1 inhibitors, acting downstream of AKT, have the disadvantage of activating AKT via feed-back mechanisms. We now evaluated the antitumor efficacy of NVP-BGT226, a novel dual pan-PI3K and MTORC1/2 inhibitor, in acute leukemia.
4.NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.
Fokas E1, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ. Radiat Oncol. 2012 Mar 27;7:48. doi: 10.1186/1748-717X-7-48.
BACKGROUND: The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is activated in tumor cells and promotes tumor cell survival after radiation-induced DNA damage. Because the pathway may not be completely inhibited after blockade of PI3K itself, due to feedback through mammalian target of rapamycin (mTOR), more effective inhibition might be expected by targeting both PI3K and mTOR inhibition.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PI3K Products


CAS 154447-36-6 LY294002

LY294002
(CAS: 154447-36-6)

LY294002 is a potent inhibitor of phosphoinositide PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively.

CAS 677338-12-4 PIK-90

PIK-90
(CAS: 677338-12-4)

PIK-90 is a potent PI3K inhibitor.

CAS 955977-50-1 PI-3065

PI-3065
(CAS: 955977-50-1)

PI-3065 is a novel potent and selective PI3K p110δ inhibitor with IC50 of 15 nM; exhibits > 100 fold selectivity against p110α, p110β, p110γ, DNA-PK and mTOR.

CAS 371935-79-4 PI-103 Hydrochloride

PI-103 Hydrochloride
(CAS: 371935-79-4)

A selective class I PI3K inhibitor; it inhibits PI3K p110 isoforms, mTOC1 and also DNA-PK; a valuable tool compound

CAS 1254036-66-2 GSK2292767

GSK2292767
(CAS: 1254036-66-2)

GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials....

CAS 1159824-67-5 CZC24832

CZC24832
(CAS: 1159824-67-5)

CZC24832 is the first selective inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with efficacy in in vitro and in vivo models of inflammation. Extensive target-...

CAS 1282512-48-4 Taselisib

Taselisib
(CAS: 1282512-48-4)

Taselisib, also known as GDC0032 or RG7606, is a selective, potent, orally bioavailable inhibitor of PI3Ka with a Ki = 0.2nM, and with reduced inhibitory activi...

CAS 2001571-40-8 eCF309

eCF309
(CAS: 2001571-40-8)

eCF309 is a potent and cell-permeable inhibitor of mTOR signaling (IC50 value 10 - 15 nM in vitro and in vivo) that exhibits >60-fold selectivity over PI3Ks. It...

CAS 1404231-34-0 ON 146040

ON 146040
(CAS: 1404231-34-0)

ON 146040 was highly potent in killing hematologic tumor cells with IC50 values in the 150 to 1,000 nM range. In biochemical testing, ON 146040 inhibited PI3K α...

CAS 900515-16-4 AS-252424

AS-252424
(CAS: 900515-16-4)

AS-252424 is a novel, potent PI3Kγ inhibitor (IC50 of 30 nM) with a 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.

CAS 19870-46-3 1,3-Dicaffeoylquinic acid

1,3-Dicaffeoylquinic acid
(CAS: 19870-46-3)

1,3-Dicaffeoylquinic acid, a caffeoylquinic acid derivative found in artichoke, acts as an anti-hyperlipidemic agent and activates PI3K/Akt.

CAS 944396-07-0 BKM120

BKM120
(CAS: 944396-07-0)

BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...

CAS 1201438-56-3 Duvelisib

Duvelisib
(CAS: 1201438-56-3)

Duvelisib, also known as IPI-145 and INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms o...

CAS 1431697-74-3 CAL-130

CAL-130
(CAS: 1431697-74-3)

CAL-130 is a potent and selective PI3K gamma and delta inhibitor with potential anticancer activity. Constitutive phosphoinositide 3-kinase (PI3K)/Akt activatio...

CAS 900185-02-6 PIK-294

PIK-294
(CAS: 900185-02-6)

PIK-294 is a potent PI3K inhibitor.

CAS 1007207-67-1 CH5132799

CH5132799
(CAS: 1007207-67-1)

CH5132799 is a novel class I PI3K inhibitor, which exhibited a strong inhibitory activity especially against PI3K; (IC(50)=0.014 uM). In human tumor cell lines ...

TGR-1202 hydrochloride
(CAS: 1532533-78-0)

TGR-1202 hydrochloride is the hydrochloride salt of TGR-1202.TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which i...

IPI-549
(CAS: 1693758-51-8)

IPI-549, a dihydroisoquinolin derivative, has been found to be a phosphatidylinositol 3 kinase gamma inhibitor, could exhibit antineoplastic activity in solid t...

CAS 648450-29-7 AS-605240

AS-605240
(CAS: 648450-29-7)

AS605240 is a selective PI3Kgamma inhibitor, has been proved effective on several inflammatory diseases. Orally administration of AS605240 significantly prevent...

CAS 870281-34-8 Acalisib

Acalisib
(CAS: 870281-34-8)

Acalisib, also known as GS-9820,  is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) ...

Chemical Structure

CAS 1245537-68-1 BGT226 (NVP-BGT226)

Quick Inquiry

Verification code

Featured Items